3/17/2020 8:08:40 AM
Cortexyme Posts Q4 Net Loss Of $12.4 Mln Or $0.46 Per Basic Share
3/16/2020 8:24:53 AM
Cortexyme Says GAIN Trial In Alzheimer's Disease Reaches Enrollment
Milestone Of 300 Patients
1/13/2020 8:10:19 AM
Cortexyme Initiates Open-Label Extension Study For
GAIN Trial Of COR388 In Alzheimer's Disease
6/19/2019 8:20:01 AM
Cortexyme Adds Jeffrey Cummings, David Hosford, Lon Schneider And Pierre Tariot To Clinical Advisory Board
5/8/2019 10:01:41 PM
Cortexyme Prices IPO Of 4.41 Mln Shares At $17.00/shr